Qi-Ying Hu

Company: Corti Therapeutics

Job title: Chief Executive Officer

Seminars:

The Development of scLNP for Extrahepatic RNA Delivery 2:15 pm

Showcasing an overview of Corti’s scLNP platform Highlighting a case study example of scLNP enabled selective delivery of RNA to disease relevant cells Illustrating the immunological considerations of non-viral delivery system and the feature of scLNPsRead more

day: Day 1

Expert Panel Discussion – De-Risking RNA Delivery Platforms Through Uncovering the Most Suitable Platforms for Your RNA Payloads to Ensure Effective Treatment 9:00 am

With an array of nonviral delivery carriers in development, how do you identify which is the most suitable method for your RNA therapeutic? How can the field leverage and learn from approved carriers, such as LNPs, to overcome 2024 IP complexities? When developing a novel delivery vehicle, how is the field de-risking their platforms to…Read more

day: Day 1